Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.72 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.72 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.72 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL8611502 | 0.89 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11 | |
| Morpholine SCHEMBL7458976 | 0.85 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL8220907 | 0.84 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| Morpholine SCHEMBL6421184 | 0.78 | MAPK13 (0.49) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL7611282 | 0.77 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11 | |
| Morpholine SCHEMBL4593148 | 0.77 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL20550934 | 0.75 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL4916578 | 0.74 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL4585949 | 0.72 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL23795665 | 0.72 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809499-A4 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORP (US) | 1998-10-14 | — | — | EP | claimed |
| EP-0809499-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | claimed |
| WO-1996021452-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | claimed |
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1545535-A4 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| US-6103936-A | REACTING ALDEHYDE, SULFIDE, SULFONE, OR SULFOXIDE WITH FORMAMIDE IN PRESENCE OF ACID CATALYST, AND OPTIONALLY A DEHYDRATING AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| US-6096739-A | Treatment for CNS injuries | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-5969184-A | INTERMEDIATES FOR COMPOUNDS WHICH CONTROL PRODUCTION OF EXCESSIVE INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0889888-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997035856-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | MAPK14 23/4885MAPK13 15/4885MAPK12 30/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | MAPK14 36/4885MAPK13 39/4885MAPK12 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.